Allena Pharmaceuticals

Allena Pharmaceuticals is a late-stage, clinical biopharmaceutical company focused on developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The company's main product candidate, reloxaliase, is an oral enzyme therapeutic that the company is developing for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease (CKD) and end-stage renal disease. The company's second product candidate, ALLN-346, is for patients with hyperuricemia and gout in the setting of CKD.
  • TickerALNA
  • ISINUS0181191075
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Liana Moussatos ... (+2)
  • Liana Moussatos
  • Andreas Argyrides
 PRESS RELEASE
ALNA Allena Pharmace... (Health Care)

Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing ...

Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) NEWTON, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the granting of inducement awards to two new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were made as a material inducement to each employee’s entry into employment...

 PRESS RELEASE
ALNA Allena Pharmace... (Health Care)

Allena Pharmaceuticals to Host Key Opinion Leader Webinar Focused on A...

Allena Pharmaceuticals to Host Key Opinion Leader Webinar Focused on ALLN-346 for the Treatment of Gout in Patients with Chronic Kidney Disease Webinar Scheduled for Wednesday, June 16th @ 12 pm EDT NEWTON, Mass., June 08, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it will host a key opinion leader (KOL) webinar focused on ALLN-346, a novel o...

Liana Moussatos ... (+3)
  • Liana Moussatos
  • Shveta Dighe
  • Andreas Argyrides
 PRESS RELEASE
ALNA Allena Pharmace... (Health Care)

Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing ...

Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) NEWTON, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the granting of an inducement award to a new employee. In accordance with NASDAQ Listing Rule 5635(c)(4), the award was approved by Allena’s Compensation Committee and made as a material inducem...

Liana Moussatos ... (+2)
  • Liana Moussatos
  • Andreas Argyrides
 PRESS RELEASE
ALNA Allena Pharmace... (Health Care)

Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing ...

Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) NEWTON, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the granting of inducement awards to two new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were made as a material inducement to each employee’s entry into employment...

 PRESS RELEASE
ALNA Allena Pharmace... (Health Care)

Allena Pharmaceuticals to Host Key Opinion Leader Webinar Focused on A...

Allena Pharmaceuticals to Host Key Opinion Leader Webinar Focused on ALLN-346 for the Treatment of Gout in Patients with Chronic Kidney Disease Webinar Scheduled for Wednesday, June 16th @ 12 pm EDT NEWTON, Mass., June 08, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it will host a key opinion leader (KOL) webinar focused on ALLN-346, a novel o...

Liana Moussatos ... (+3)
  • Liana Moussatos
  • Shveta Dighe
  • Andreas Argyrides
 PRESS RELEASE
ALNA Allena Pharmace... (Health Care)

Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing ...

Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) NEWTON, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the granting of an inducement award to a new employee. In accordance with NASDAQ Listing Rule 5635(c)(4), the award was approved by Allena’s Compensation Committee and made as a material inducem...

Liana Moussatos ... (+2)
  • Liana Moussatos
  • Andreas Argyrides
 PRESS RELEASE
ALNA Allena Pharmace... (Health Care)

Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing ...

Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) NEWTON, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the granting of inducement awards to two new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were made as a material inducement to each employee’s entry into employment...

 PRESS RELEASE
ALNA Allena Pharmace... (Health Care)

Allena Pharmaceuticals to Host Key Opinion Leader Webinar Focused on A...

Allena Pharmaceuticals to Host Key Opinion Leader Webinar Focused on ALLN-346 for the Treatment of Gout in Patients with Chronic Kidney Disease Webinar Scheduled for Wednesday, June 16th @ 12 pm EDT NEWTON, Mass., June 08, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it will host a key opinion leader (KOL) webinar focused on ALLN-346, a novel o...

Liana Moussatos ... (+3)
  • Liana Moussatos
  • Shveta Dighe
  • Andreas Argyrides
 PRESS RELEASE
ALNA Allena Pharmace... (Health Care)

Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing ...

Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) NEWTON, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the granting of an inducement award to a new employee. In accordance with NASDAQ Listing Rule 5635(c)(4), the award was approved by Allena’s Compensation Committee and made as a material inducem...

Liana Moussatos ... (+2)
  • Liana Moussatos
  • Andreas Argyrides
 PRESS RELEASE
ALNA Allena Pharmace... (Health Care)

Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing ...

Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) NEWTON, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the granting of inducement awards to two new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were made as a material inducement to each employee’s entry into employment...

 PRESS RELEASE
ALNA Allena Pharmace... (Health Care)

Allena Pharmaceuticals to Host Key Opinion Leader Webinar Focused on A...

Allena Pharmaceuticals to Host Key Opinion Leader Webinar Focused on ALLN-346 for the Treatment of Gout in Patients with Chronic Kidney Disease Webinar Scheduled for Wednesday, June 16th @ 12 pm EDT NEWTON, Mass., June 08, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it will host a key opinion leader (KOL) webinar focused on ALLN-346, a novel o...

Liana Moussatos ... (+3)
  • Liana Moussatos
  • Shveta Dighe
  • Andreas Argyrides
 PRESS RELEASE
ALNA Allena Pharmace... (Health Care)

Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing ...

Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) NEWTON, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the granting of an inducement award to a new employee. In accordance with NASDAQ Listing Rule 5635(c)(4), the award was approved by Allena’s Compensation Committee and made as a material inducem...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch